Helus Pharma’s Modified Psilocybin Achieves Phase 3 Trial Goals in Major Depression
By Dr. Zubair Khalid, DVM, MS, PhD ·

Helus Pharma announced that its oral, chemically modified version of psilocybin met the key goals of a Phase 3 clinical trial. The study evaluated the drug as an adjunctive treatment for patients with major depressive disorder. The company reported the positive results, though specific numerical data and additional details have not yet been released.
The trial assessed the safety and efficacy of Helus’s synthetic psilocybin analog when added to standard antidepressant therapy. The drug is designed to preserve the therapeutic benefits of psychedelic compounds while potentially reducing side effects such as hallucinogenic experiences or cardiovascular strain. Helus has not disclosed the exact chemical modification or the trial’s timeline beyond the Phase 3 readout.
Relevance to Life Sciences
This result adds momentum to the growing field of psychedelic-assisted therapy. Major depressive disorder affects millions worldwide, and many patients do not respond adequately to existing antidepressants. A chemically modified psilocybin that can be taken orally and with a controlled safety profile could offer a new treatment pathway. The data also highlight the potential for synthetic analogs to address regulatory and practical challenges seen with natural psychedelics, such as variability in dosing and duration of effect. Success in Phase 3 is a critical step toward regulatory approval and eventual clinical adoption.
Source: original report